Xconomy San Francisco – Amber Salzman has resigned from her position as president and CEO of Adverum Biotechnologies (NASDAQ: ADVM) effective May 3. She has also stepped down from the Menlo Park, CA, gene therapy developer’s board.
Name: Amber Salzman
Continent: North America
Company: Adverum Biotechnologies
Position: CEO & President
Announcement Date: May 03, 2018, 10:00pm
Resignation Date: May 03, 2018, 10:00pm